File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A randomized double-blinded placebo-controlled trial on the effect of dehydroepiandrosterone for 16 weeks on ovarian response markers in women with primary ovarian insufficiency

TitleA randomized double-blinded placebo-controlled trial on the effect of dehydroepiandrosterone for 16 weeks on ovarian response markers in women with primary ovarian insufficiency
Authors
Issue Date2013
PublisherThe Endocrine Society. The Journal's web site is located at http://jcem.endojournals.org
Citation
Journal of Clinical Endocrinology and Metabolism, 2013, v. 98 n. 1, p. 1-9 How to Cite?
AbstractContext: Preliminary reports have shown encouraging effects of dehydroepiandrosterone (DHEA) in women with poor ovarian reserve undergoing assisted reproduction and primary ovarian insufficiency (POI), although data from randomized controlled trials are limited. The present study assesses the effect of DHEA on ovarian response markers in women with POI. Objective: The objective of the study was to evaluate whether DHEA for 16 wk would improve ovarian response markers in women with POI. Design: This was a randomized, double-blinded, placebo-controlled study. Setting: The study was conducted at a tertiary reproductive unit. Patients: Twenty-two women with unexplained POI participated in the study. Interventions: Eligible subjects were randomized into the DHEA group (n = 10), who received DHEA (LiveWell, 25 mg three times a day), or the placebo group (n = 12), who received placebo for 16 wk according to a computer-generated randomization list. Ovarian response markers included serum anti-Mullerian hormone (AMH), FSH levels, and antral follicle count (AFC) as well as follicles of 10 mm or greater in diameter, and hormonal profiles were measured at 4-wk intervals until 4 wk after completion of treatment. Any returns of menses and side effects from treatment were recorded. Main Outcome Measures: The primary outcome was serum AMH level. Results: No significant change in serum AMH and FSH levels had been detected throughout the study. AFC and ovarian volume were significantly higher at wk 12 and 20, respectively, in the DHEA group. Significantly more women having at least one follicle of 10 mm or greater at wk 12, 16, and 20 were found in the DHEA group. Serum testosterone and DHEA sulfate levels along with higher estradiol levels were significantly higher in the DHEA group. Conclusion: This randomized, double-blinded, placebo-controlled trial found higher AFC and ovarian volume at wk 12 and 20, respectively, in the DHEA group, although there were no significant changes in serum AMH and FSH levels. Further trials using a longer duration of DHEA should be considered to evaluate the long-term effect of DHEA in women with POI.
Persistent Identifierhttp://hdl.handle.net/10722/181099
ISSN
2017 Impact Factor: 5.789
2015 SCImago Journal Rankings: 2.940
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorYeung, TWY-
dc.contributor.authorLi, RHW-
dc.contributor.authorLee, VCY-
dc.contributor.authorHo, PC-
dc.contributor.authorNg, EHY-
dc.date.accessioned2013-02-19T11:35:07Z-
dc.date.available2013-02-19T11:35:07Z-
dc.date.issued2013-
dc.identifier.citationJournal of Clinical Endocrinology and Metabolism, 2013, v. 98 n. 1, p. 1-9-
dc.identifier.issn0021-972X-
dc.identifier.urihttp://hdl.handle.net/10722/181099-
dc.description.abstractContext: Preliminary reports have shown encouraging effects of dehydroepiandrosterone (DHEA) in women with poor ovarian reserve undergoing assisted reproduction and primary ovarian insufficiency (POI), although data from randomized controlled trials are limited. The present study assesses the effect of DHEA on ovarian response markers in women with POI. Objective: The objective of the study was to evaluate whether DHEA for 16 wk would improve ovarian response markers in women with POI. Design: This was a randomized, double-blinded, placebo-controlled study. Setting: The study was conducted at a tertiary reproductive unit. Patients: Twenty-two women with unexplained POI participated in the study. Interventions: Eligible subjects were randomized into the DHEA group (n = 10), who received DHEA (LiveWell, 25 mg three times a day), or the placebo group (n = 12), who received placebo for 16 wk according to a computer-generated randomization list. Ovarian response markers included serum anti-Mullerian hormone (AMH), FSH levels, and antral follicle count (AFC) as well as follicles of 10 mm or greater in diameter, and hormonal profiles were measured at 4-wk intervals until 4 wk after completion of treatment. Any returns of menses and side effects from treatment were recorded. Main Outcome Measures: The primary outcome was serum AMH level. Results: No significant change in serum AMH and FSH levels had been detected throughout the study. AFC and ovarian volume were significantly higher at wk 12 and 20, respectively, in the DHEA group. Significantly more women having at least one follicle of 10 mm or greater at wk 12, 16, and 20 were found in the DHEA group. Serum testosterone and DHEA sulfate levels along with higher estradiol levels were significantly higher in the DHEA group. Conclusion: This randomized, double-blinded, placebo-controlled trial found higher AFC and ovarian volume at wk 12 and 20, respectively, in the DHEA group, although there were no significant changes in serum AMH and FSH levels. Further trials using a longer duration of DHEA should be considered to evaluate the long-term effect of DHEA in women with POI.-
dc.languageeng-
dc.publisherThe Endocrine Society. The Journal's web site is located at http://jcem.endojournals.org-
dc.relation.ispartofJournal of Clinical Endocrinology and Metabolism-
dc.titleA randomized double-blinded placebo-controlled trial on the effect of dehydroepiandrosterone for 16 weeks on ovarian response markers in women with primary ovarian insufficiency-
dc.typeArticle-
dc.identifier.emailYeung, TWY: twyyeung@hku.hk-
dc.identifier.emailLi, RHW: raymondli@hku.hk-
dc.identifier.emailLee, VCY: v200lee@hku.hk-
dc.identifier.emailHo, PC: pcho@hku.hk-
dc.identifier.emailNg, EHY: nghye@hku.hk-
dc.identifier.authorityLi, RHW=rp01649-
dc.identifier.authorityHo, PC=rp00325-
dc.identifier.authorityNg, EHY=rp00426-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1210/jc.2012-3071-
dc.identifier.pmid23144466-
dc.identifier.scopuseid_2-s2.0-84872093689-
dc.identifier.hkuros213334-
dc.identifier.volume98-
dc.identifier.issue1-
dc.identifier.spage1-
dc.identifier.epage9-
dc.identifier.isiWOS:000316210300074-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats